Please assess the completion status of the following clinical trial:

Trial Title: Canakinumab in Patients With Active Hyper-IgD Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a diagnosis of HIDS proven by DNA analysis and/or enzymatic studies.~2. At time of start of drug treatment: active HIDS as evidenced by a physician global assessment of HIDS flare severity ≥ 2 and CRP values \>10 mg/L (normal CRP \< or = 10 mg/L).~3. Patients who have a history of \> or = 3 febrile acute HIDS flares in a 6-month period when not receiving prophylaxis treatment (e.g. anakinra daily treatment) with a duration of each flare lasting \> or = 4 days and limiting the normal daily activities.~Exclusion Criteria:~1. Pregnant or nursing (lactating) women.~2. History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot) test result.~3. Positive Hepatitis B or Hepatitis C.~4. Live vaccinations within 3 months prior to the start of the trial~5. Positive tuberculosis screening test.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).